Free Trial
NASDAQ:NTRB

Nutriband 9/3/2024 Earnings Report

Nutriband logo
$7.54 -0.53 (-6.57%)
Closing price 07/29/2025 04:00 PM Eastern
Extended Trading
$8.18 +0.64 (+8.44%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nutriband EPS Results

Actual EPS
-$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nutriband Revenue Results

Actual Revenue
$0.44 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nutriband Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nutriband's next earnings date is estimated for Tuesday, September 2, 2025, based on past reporting schedules.

Conference Call Resources

Nutriband Earnings Headlines

A grave, grave error.
Nvidia just hit $4 trillion… but a tech apocalypse may already be underway. A controversial new documentary, The Final Frontier, exposes the hidden dangers behind the AI boom—and why investors in big tech could soon face massive losses. It also reveals the #1 little-known company to buy now.
See More Nutriband Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email.

About Nutriband

Nutriband (NASDAQ:NTRB) develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

View Nutriband Profile

More Earnings Resources from MarketBeat